- Home
- ADCT vs NB Comparison
ADCT vs NB Comparison
Compare ADCT & NB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- NB
- Stock Information
- Founded
- ADCT 2011
- NB 1987
- Country
- ADCT Switzerland
- NB United States
- Employees
- ADCT N/A
- NB N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- NB Metal Mining
- Sector
- ADCT Health Care
- NB Basic Materials
- Exchange
- ADCT Nasdaq
- NB Nasdaq
- Market Cap
- ADCT 241.0M
- NB 231.0M
- IPO Year
- ADCT 2020
- NB N/A
- Fundamental
- Price
- ADCT $2.69
- NB $3.16
- Analyst Decision
- ADCT Strong Buy
- NB Strong Buy
- Analyst Count
- ADCT 6
- NB 2
- Target Price
- ADCT $7.80
- NB $4.50
- AVG Volume (30 Days)
- ADCT 663.5K
- NB 2.9M
- Earning Date
- ADCT 08-12-2025
- NB 09-12-2025
- Dividend Yield
- ADCT N/A
- NB N/A
- EPS Growth
- ADCT N/A
- NB N/A
- EPS
- ADCT N/A
- NB N/A
- Revenue
- ADCT $75,817,000.00
- NB N/A
- Revenue This Year
- ADCT $11.75
- NB N/A
- Revenue Next Year
- ADCT $8.56
- NB N/A
- P/E Ratio
- ADCT N/A
- NB N/A
- Revenue Growth
- ADCT 10.49
- NB N/A
- 52 Week Low
- ADCT $1.05
- NB $1.27
- 52 Week High
- ADCT $3.97
- NB $4.36
- Technical
- Relative Strength Index (RSI)
- ADCT 40.85
- NB 53.83
- Support Level
- ADCT $2.84
- NB $2.64
- Resistance Level
- ADCT $3.19
- NB $3.41
- Average True Range (ATR)
- ADCT 0.19
- NB 0.29
- MACD
- ADCT -0.06
- NB -0.06
- Stochastic Oscillator
- ADCT 12.66
- NB 30.23
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.